Is Axovant Gene Therapies a Buy?
The small-cap biopharma started 2019 with a rising stock price and a new focus on gene therapies, but it's been a rocky transition.
Axovant Gene Therapies Ltd.
AXGT
AXGT
$5.53
-$0.07
-1.2%
BATS BZX Real Time Price as of December 13, 2019, 4:00 p.m. EST
View Interactive AXGT Charts
News & Analysis: Axovant Gene Therapies Ltd.
Here's Why Axovant Gene Therapies Dropped as Much as 16.6% Today
The biopharma is wisely taking advantage of its lofty stock price to raise capital through a share offering.
Here's Why Axovant Gene Therapies Rocketed Higher Today
Investors are excited about new clinical results suggesting the small-cap biopharma is on to something big.
Here's Why Axovant Sciences Lost as Much as 29.2% Today
The biopharma's wild year continues with another clinical failure, but it won't have much impact on the company's future.
Here's Why Axovant Sciences Fell as Much as 21.3% Today
The meteoric rise in recent weeks is proving unsustainable.
Why Xunlei, Griffon, and Axovant Sciences Slumped Today
Find out why these stocks got smacked down the hardest.
3 Drug Stocks That Soared This Week: Are They Buys?
Can these red-hot drug stocks keep the momentum going?
Why Camping World Holdings, Axovant Sciences, and Sonic Jumped Today
Find out what tasty news one restaurant chain offered to investors.
Here's Why Axovant Sciences Stock Skyrocketed Today
Can the company treat Parkinson's disease with gene therapy?
Why Dave & Buster's Entertainment, Axovant Sciences, and Five Below Slumped Today
Even on another solid market day, these stocks fell. Find out why.
